Giuseppe
Emeritus
[Source: Journal of Virology, full page: (LINK). Abstract, edited.]
Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies
Fei Song<SUP>a</SUP>, Robert Fux<SUP>a</SUP>, Lisette B. Provacia<SUP>b</SUP>, Asisa Volz<SUP>a</SUP>, Markus Eickmann<SUP>c</SUP>, Stephan Becker<SUP>c</SUP>,<SUP>d</SUP>, Albert D. M. E. Osterhaus<SUP>b</SUP>, Bart L. Haagmans<SUP>b</SUP> and Gerd Sutter<SUP>a</SUP>,<SUP>d</SUP>
<SUP></SUP>
Author Affiliations: Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Munich, Germany<SUP>a </SUP>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands<SUP>b </SUP>Institute of Virology, Philipps University Marburg, Marburg, Germany<SUP>c</SUP>
<SUP></SUP>
German Centre for Infection Research (DZIF)<SUP>d</SUP><SUP>?</SUP>
<SUP></SUP>
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.
FOOTNOTES
Received 18 June 2013. Accepted 19 August 2013.
Address correspondence to Gerd Sutter, gerd.sutter@lmu.de.
? For this virtual institution, see http://www.dzif.de/en/.
Published ahead of print 28 August 2013
Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
------
Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies
Fei Song<SUP>a</SUP>, Robert Fux<SUP>a</SUP>, Lisette B. Provacia<SUP>b</SUP>, Asisa Volz<SUP>a</SUP>, Markus Eickmann<SUP>c</SUP>, Stephan Becker<SUP>c</SUP>,<SUP>d</SUP>, Albert D. M. E. Osterhaus<SUP>b</SUP>, Bart L. Haagmans<SUP>b</SUP> and Gerd Sutter<SUP>a</SUP>,<SUP>d</SUP>
<SUP></SUP>
Author Affiliations: Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Munich, Germany<SUP>a </SUP>Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands<SUP>b </SUP>Institute of Virology, Philipps University Marburg, Marburg, Germany<SUP>c</SUP>
<SUP></SUP>
German Centre for Infection Research (DZIF)<SUP>d</SUP><SUP>?</SUP>
<SUP></SUP>
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.
FOOTNOTES
Received 18 June 2013. Accepted 19 August 2013.
Address correspondence to Gerd Sutter, gerd.sutter@lmu.de.
? For this virtual institution, see http://www.dzif.de/en/.
Published ahead of print 28 August 2013
Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
------